Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 9 participants, all of whom received a treatment called Photodynamic Therapy (PDT) — a procedure that uses a light-sensitive drug and a special light source to target diseased tissue in the lining of the lung (the pleura). The trial set out to measure several things: any harmful side effects from the treatment, how long participants lived after receiving it, how long it took for the disease to progress in the pleural area specifically, how long it took for the disease to progress anywhere in the body, and how much of the PDT drug was absorbed. The reported data shows that none of the 9 participants were recorded as having completed the study, with all 9 listed under "not completed." The reported data shows that, unfortunately, no numerical results were submitted to ClinicalTrials.gov for any of the outcome measures — whether for side effects, survival, disease progression, or drug absorption. This means there are no figures available to describe for any of these measurements. It is not possible to say what the trial found in terms of numbers, as this information was not reported in the publicly available data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Lung Cancer Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with non-small cell lung cancer (a type of lung cancer), confirmed by a tissue sample test
- Your cancer has spread to the lining around the lungs (the pleura), shown by medical or tissue evidence
- Your main lung tumor has been assessed by a chest surgeon and can be surgically removed
- You have received or are currently receiving between two and four rounds of standard first-line chemotherapy for your cancer
- You are healthy enough to safely have surgery
Who may not be able to join:
- You have significantly elevated liver enzyme levels in your blood (confirm with trial site)
- Your bilirubin level (a substance measured in blood related to liver function) is above 1.5 mg/dL
- You have a known HIV infection
- You are currently pregnant or breastfeeding
- You have had any previous treatment for this lung cancer other than a procedure to drain fluid around the lungs (pleurodesis) or standard first-line chemotherapy
- You have previously been treated with a chemotherapy drug called pemetrexed disodium
- You have previously received a type of radiation treatment to the chest and neck area called mantle radiotherapy
- You are currently receiving chemotherapy or radiotherapy at the same time as the main study treatment period (though radiation after surgery may be given if medically needed)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Toxicity Assessment of Pleural Photodynamic Therapy; Overall Survival; Pleural Progression-free Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.